Two Wharton graduates founded BioPhy to use artificial intelligence to accurately predict the outcomes of drug trials.
Credit: Abhiram JuvvadiWharton graduates Dave Latshaw II and Steven Truong claim they can use artificial intelligence to predict the outcomes of drug trials with 80 percent accuracy with their company BioPhy.
BioPhy launched their AI software, called BioLogicAI, this month and received a $4.5 million funding from numerous investors, including a company co-founded by Chelsea Clinton. The AI software can assist pharmaceutical companies in finding the most helpful products and expediting their market entry.
BioPhy conducted more than 1,500 drug trials to reach their 80% accuracy, Latshaw told The Philadelphia Inquirer. BioPhy is also currently striving to improve drug development by allowing companies to improve the structure of trials for specific drugs. BioPhy plans to work with companies to maximize the success of their drug trials.
Latshaw highlighted that their AI tools can assess both new and established drugs since it was exposed to a database of over 450,000 trials across all three testing phases. The model accounts for trial location and patient demographics.
BioPhy has two AI products, BioLogicAI and BioPhyRx. BioLogicAI is dedicated to predicting personalized information on drug developers and BioPhyRx is an AI research assistant that can provide information about the “scientific and regulatory landscape,” according to USA Today. Both AI tools aim to help improve drug trial efficiency.
The AI tells users if the trial will achieve its primary endpoint through a simple yes-or-no answer, according to the Inquirer.
“Our goal is straightforward: make drug development faster and more reliable. This benefits everyone, from researchers to patients," Latshaw told USA Today.
The Daily Pennsylvanian is an independent, student-run newspaper. Please consider making a donation to support the coverage that shapes the University. Your generosity ensures a future of strong journalism at Penn.
Donate